Disease · MONDO_0018076
Comparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 37
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events | 126 of 408 | 153 of 404 | 812 | NCT00255840 | Trial comparisons |
| Standard TB Treatment vs Double Rimfampicin: deaths from any cause | 17 of 348 | 12 of 353 | 701 | NCT02153528 | Trial comparisons |
| Standard TB Treatment vs Double Rimfampicin: serious adverse events | 24 of 348 | 13 of 353 | 701 | NCT02153528 | Trial comparisons |
| Standard TB Treatment vs Double Rimfampicin: Number of Participants Who Develop Liver Toxicity | 7 of 343 | 3 of 350 | 693 | NCT02153528 | Trial comparisons |
| 3HP Self Administered Therapy (SAT) vs 3HP SAT With SMS Reminders: Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders | 248 of 335 | 250 of 326 | 661 | NCT01582711 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: Discontinuation Due to Experiencing an Adverse Event | 10 of 156 | 1 of 156 | 312 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: deaths from any cause | 0 of 156 | 0 of 156 | 312 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: serious adverse events | 0 of 156 | 0 of 156 | 312 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Adherence | 9 of 152 | 117 of 153 | 305 | NCT03089983 | Trial comparisons |
| Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Completion Rates in Prison | 114 of 152 | 127 of 153 | 305 | NCT03089983 | Trial comparisons |
| Double Rifampicin Arm Negative on Auramine Smear vs Double Rifampicin Group Negative on FDA Smear: the Negative Predictive Value of Conversion at 2 Weeks for Relapse. | 0 of 91 | 0 of 193 | 284 | NCT02153528 | Trial comparisons |
| Delamanid 100 mg BID + OBR vs Delamanid 200 mg BID + OBR: Number of Participants With Abnormality in Audiometry at Baseline | 90 of 137 | 34 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100mg BID + OBR vs Delamanid 200mg BID + OBR: Number of Participants With Clinical Significant Abnormality in Thyroid Function Test Reported as TEAE | 0 of 137 | 1 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100 mg BID + OBR vs Delamanid 200 mg BID + OBR: Number of Participants With Any Concomitant Medication Usage | 135 of 137 | 75 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100 mg BID + OBR vs Delamanid 200 mg BID + OBR: deaths from any cause | 1 of 137 | 0 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100 mg BID + OBR vs Delamanid 200 mg BID + OBR: Number of Participants With Abnormality in Visual Acuity | 45 of 137 | 35 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100 mg BID + OBR vs Delamanid 200 mg BID + OBR: serious adverse events | 19 of 137 | 6 of 76 | 213 | NCT02573350 | Trial comparisons |
| Delamanid 100mg BID + OBR vs Delamanid 200mg BID + OBR: Number of Participants With Clinical Significant Abnormality in Cortisol | 44 of 136 | 19 of 76 | 212 | NCT02573350 | Trial comparisons |
| Moxifloxacin vs Control: Proportion of Patients With Any Grade 3 or 4 Adverse Reactions in the Two Study Arms | 43 of 98 | 25 of 98 | 196 | NCT02114684 | Trial comparisons |
| Moxifloxacin vs Control: deaths from any cause | 6 of 98 | 4 of 98 | 196 | NCT02114684 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018076/comparisons